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ABSTRACT 
The C9orf72 expansion is considered a major genetic cause of familial frontotemporal dementia 
(FTD) in several patients’ cohorts. Interestingly, C9orf72 expansion carriers, present also 
abundant neuronal p62- positive inclusions. Although p62/SQSTM1 mutations were initially 
associated with Paget disease of bone (PDB), they have been also identified in FTD. We describe 
a FTD-PDB family in which the proband presented with behavioral FTD phenotype and 
concomitant Paget disease. The molecular genetic analysis revealed the co-occurrence of two 
mutations; the pathogenic C9orf72 expansion and p.P392L heterozygous missense mutation in 
SQSTM1 gene. Amongst the six family members analyzed, the p.P392L SQSTM1 mutation 
segregated as expected with PDB whereas the C9orf72 expansion segregated with frontal 
cognitive impairment or dementia in all but one carrier. The coexistence of these conditions 
could be underestimated since neither patients with FTD nor patients with PDB undergo bone 
scintingraphy or cognitive assessment, respectively. The number of cases with double mutations 
could also be over looked as the molecular strategy adopted in the majority of laboratories ends 
with the identification of one pathogenic mutation in one of the known causative genes. 
Therefore, we advocate for further clinical and molecular evaluation in suspect cases. 
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INTRODUCTION 
A pathogenic expansion of hexanucleotide (G4C2) repeat upstream of the C9orf72 coding region in the first intron or 
the promoter region depending on the transcript variant was identified as a major cause of familial frontotemporal 
lobar degeneration (FTLD) and/or amyotrophic lateral sclerosis (ALS) in several cohorts from different 
geographical regions (Dejesus-Hernandez et al., 2011; Gijselinck et al., 2012; Renton et al., 2011; van der Zee et al., 
2013). The repeat units in patients were estimated to be several hundred to several thousand, compared to less than 
25 repeat units in healthy controls (Gijselinck et al., 2012; van der Zee et al., 2013).  Patients carrying the repeat 
expansion show a high degree of heterogeneity in clinical phenotypes, even in the same family (Cerami et al., 2013).  
Atypical symptoms have been reported and include cognitive impairment, psychosis and extrapyramidal dysfunction 
(Boeve et al., 2012; Galimberti et al., 2013; Snowden et al., 2012). It is of interest to note that, FTLD or ALS 
patients carrying the C9orf72 gene expansion, present also abundant neuronal p62- positive inclusions (Al-Sarraj et 
al., 2011; Murray et al., 2011). The increased p62 immunoreactivity is common to a wide variety of 
neurodegenerative diseases, such as Alzheimer disease (AD), dementia with Lewy bodies, FTLD, Parkinson disease 
(PD), and Huntington disease (HD) (Kuusisto et al 2001; Nakaso et al., 2004; Zatloukal et al., 2002). p62 protein, 
encoded by sequestosome 1 (SQSTM1) gene located on chromosome 5q35 is a multifunctional protein that contains 
several domains, including PB1, ZZ, TRAF6, PEST, and the ubiquitin-binding domain (UBA). Although mutations 
in this gene were initially identified as a cause of Paget disease of bone (PDB) (Laurin et al., 2002), in 2011 
SQSTM1 mutations were also reported in ALS (Fecto et al., 2011).  Recently SQSTM1 mutations have been 
identified in patients with FTLD from different geographical regions, suggesting its role also in the pathogenesis of 
this neurodegenerative disease (Le Ber et al., 2013; Rubino et al., 2012; van der Zee et al 2014).  Interestingly, some 
of these FTLD SQSTM1 mutation carriers also developed signs and symptoms of PDB (Le Ber et al., 2013).  
However, due to the low penetrance of Paget disease, the coexistence of these conditions could be underestimated 
since neither patients with FTLD nor patients with PDB undergo bone scintingraphy or cognitive assessment, 
respectively. Amongst its multiple cellular functions, the p62 plays a key role in the regulation of osteoclast 
differentiation as well as their activity and survival. In addition, it has a crucial role in targeting misfolded and/or 
ubiquitinated proteins for degradation by autophagy or by the ubiquitin–proteasome systems (Bjørkøy et al., 2006; 
Pankiv et al., 2007; Seibenhener et al., 2004).  Interestingly, all mutations identified in the PDB patients were 
clustered either within or near the UBA domain, impairing the ability of p62 to bind to ubiquitin (Cavey et al., 2006; 
Najat et al., 2009), probably resulting in aberrant NF-jB signaling (Vadlamuni et al., 1996). Conversely, the 
mutations identified thus far in both ALS patients and FTLD were distributed throughout the coding region of the 
gene. In these cases, p62 mutations may significantly compromise protein–protein interactions and/or the clearance 
of or promote the aggregation of ubiquitinated protein inclusions found in neurons of both patients with FTLD and 
ALS (Fecto et al., 2011; Kwok et al 2013; Le Ber et al., 2013; Rubino et al., 2012; Teyssou et al., 2013).   
The present study aims to describe a FTLD-PDB family with the coexistence of SQSTM1 mutation and 
Hexanucleotide (G4C2) Repeat Expansion in C9orf72 gene. 
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1. MATERIALS AND METHODS 
2.1 Subjects  
All the seven available family members provided a written consent for their participation in the study. All 
individuals were in a stable condition, without acute comorbidities and underwent a thorough biochemical and 
neurological evaluation performed by a behavioural neurologist from the Department of Neurology of Coimbra 
University Hospital. For all the patients detailed history, clinical neurological examination; psychiatric evaluation, 
neuropsychological assessment, brain imaging and genetic testing were done. The diagnosis of FTLD was based on 
the Lund and Manchester clinical criteria (Neary et al., 1998; The Lund  and Manchester Groups 1994)  revised by 
the Work Group on Frontotemporal Dementia and Pick’s Disease (McKhann et al., 2001) and more recently 
according to the International Behavioural Variant Frontotemporal Dementia Criteria Consortium for bvFTD 
(Rascovsky et al 2011). The diagnosis of PDB was defined as monostotic or polyostotic increased bone radionuclide 
uptake in bone scintigraphy which can be associated with raised levels of serum total alkaline phosphatase. 
 
2.2 Genetic testing 
All eight exons of the SQSTM1 gene were PCR amplified using previously reported primers flanking the intron-
exon boundaries (Michou et al., 2012) and were subsequently direct sequenced.  
The detection of the C9orf72 expansion  was performed using a two-step PCR based protocol as previously 
described (van der Zee et al., 2013) and the G4C2 repeat  sizing was determined using the new short expansion 
PCR as described (Gijselinck et al., 2015). The proband was also screened for MAPT, PGRN and VCP genes.  
 
2. RESULTS 
The pedigree is shown in Fig 1. The proband (III3) had 12 years of education , with no consistent job due to 
personality disorder. He was diagnosed with PBD at the age of 57, presenting a typical polyostotic bone disease 
in scintigraphy (Fig 2) and elevated levels of serum total alkaline phosphatase (127mg/dL). When he was 58 
years of age a neurological evaluation was requested due to the development of weakness in the lower limbs 
leading to falls with subsequently incapacity to walk unassisted as well as mental/behavior symptoms 
(desinhibition, puerility and agressivity).  The neurological assessment showed tetraparesis with predominant 
proximal weakness and general hyporreflexia, suggesting a muscle disease, but he also presented spastic speech, 
bilateral Babinski signs and ancillary reflexes (glabella, snout and grasping). The mental assessment disclosed 
psychomotor slowing, paucity of speech, echolalia, palilalia and perseveration. Mental-State Examination-MMSE 
(Portuguese version) (Folstein et al 1975; Guerreiro et al., 2003a) was abnormal (23/30) and the global score (21) 
on the Alzheimer’s disease Assessment Scale- ADAS-COG (Portuguese version) (Guerreiro 1988b; Mohs et al., 
1983) was compatible with mild to moderate cognitive deterioration. A comprehensive cognitive evaluation was 
performed with the Battery of Lisbon for the Assessment of Dementia (BLAD) (Guerreiro 1988), which includes 
multiple neuropsychological tests representing key cognitive domains and is validated for the Portuguese 
population. This evaluation confirmed frontal dysfunction with impairment in tests of motor control (Luria), 
verbal initiative (Verbal Semantic Fluency), verbal and non-verbal abstraction (Interpretation of Proverbs and the 
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Raven Progressive Matrices). Language evaluations, as well as tests related to visuo-constructional abilities 
(Clock Drawing test) were normal, except for the presence of perseverative behaviour. Routine laboratorial tests 
for treatable dementia including CSF analysis were normal. The EMG was normal and the muscle biopsy did not 
reveal any abnormal findings. Magnetic resonance imaging (MRI) of the brain showed mild cortical-subcortical 
atrophy more pronounced in the left hemisphere (Fig 3).  The single-photon emission computed tomography 
(SPECT) revealed cerebral hypoperfusion at the frontal lobe (upper frontal, pre and post central gyrus), and also 
parietal, predominantly left-sided (Fig 4). According to these results the patient was tested for mutations in 
valosin-containing protein (VCP) gene but no mutations were found. Further genetic studies in the framework of 
the European Early-Onset Dementia (EU EOD) consortium (van der Zee et al., 2013, 2014), revealed that he 
harboured both C9orf72 repeat expansion and p.P392L heterozygous missense mutation in the SQSTM1 gene. 
Using the new short expansion PCR technique, it was also demonstrated  that this patient carried a full pathogenic 
long expansion (>80 units). The patient died of lung infection in another hospital at 59 years of age, one year 
after the dementia diagnosis. The proband had a positive family history for FTLD and PDB. The proband’s 
mother (II1) had behavioral symptoms and developed dementia associated with parkinsonism and also 
complained of lower limbs pain at 60 years of age. Her DNA was not available. His maternal uncle (II2) had also 
developed Parkinsonism but without dementia in his nineties, the other uncle (II3) died at young age in the war, 
still with no clinical signs of FTLD or PDB whereas the youngest uncle (II4) developed dementia at 83 years of 
age. Although the clinical features initially suggested the diagnosis of Alzheimer Disease, the MRI of the brain 
showed a severe asymmetrical atrophy involving the hypocampus and PIB-PET was negative for amyloid 
deposits.  He carried the hexanucleotide repeat expansion in C9orf72 gene.  
The five probands’ sibs, have been tested for the two mutations previously identified in the family. The subjects III1 
and III2 (69 and 65 years of age, respectively) carried only the hexanucleotide repeat expansion in C9orf72 gene, the 
III4 (60 years of age) harboured both C9orf72 expansion and p.P392L mutation; subject III5 (57 years of age) 
carried only the p.P392L mutation, she had a history of early mental impairment as a result of encephalitis in her 
childhood and was already diagnosed with PDB; and the remaining sibling (III6) (52 years of age) had none of the 
mutations identified. Although these subjects had no subjective cognitive complaints and normal neurological 
examination, they underwent psychiatric and neuropsychological assessment and investigation of possible PDB 
diagnosis. As expected, all the three SQSTM1 p.P392L mutation carriers had the clinical imaging diagnosis of PDB, 
whereas the non carriers presented a negative scintigraphy. Therefore, this mutation segregated with PBD with full 
penetrance at 60 years of age in this family. Considering neuropsychological and psychiatric evaluation, the subjects 
III1 and III2 (C9orf72 expansion carriers) presented mild frontal behavioral and cognitive impairment (impulsivity, 
perseveration, deficit in attention and mild learning disorder). Patients III5 had multiple deficits congruent with the 
information of development cognitive impairment. Finally, the subjects III4 (double mutation carrier) and III6 
(without mutations) had no mental decline. Considering the seven family members tested in both generations, the 
C9orf72 repeat expansion segregated with frontal cognitive impairment in all but one carrier (III4). Curiously, there 
is only one case (III5) who harbors only the SQSTM1 p.P392L mutation but unfortunately it is not completely 
informative in respect of its association with cognitive impairment due to a previous history of mental development 
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disorder, although there is no insight of cognitive deterioration (The clinical characteristics of the patients and their 
neuropsychological and psychological evaluations are summarized in Table 1 and Table 2).  
 
3. DISCUSSION 
We describe a family with both FTD and PDB carrying the c.1175C>T, p.P392L mutation in exon 8 of the SQSTM1 
gene and a long repeat expansion (>80 units) in C9orf72 gene. Amongst the six family members analyzed, the 
C9orf72 repeat expansion segregated with frontal cognitive impairment or dementia in all but one carrier whereas 
the p.P392L SQSTM1 mutation segregated with the PDB in all carrier members. This SQSTM1 mutation identified 
was located in the UBA domain of the p62 protein and is considered the most frequent mutation among both familial 
and sporadic PDB patients (Nakaso et al., 2004). Interestingly, it was also identified in FTLD, ALS patients (with or 
without concomitant PDB) and in control individuals at low frequency (<1%) (Adzhubei et al., 2010; Fecto et al., 
201; Laurin et al., 2002; Vadlamudi et al., 1996). More recently, it was also found to segregate with dementia in a 
FTLD-PDB family (Le Ber et al., 2013) and in a familial ALS-PDB (Kumar et al., 2009; Najat et al., 2009). 
Curiously, we also have previously identified, in the framework of the EU EOD consortium (data not shown), three 
Portuguese bvFTD patients harbouring this particular mutation, p.P392L, thereby supporting the role for SQSTM1 as 
a causative gene in FTLD since they had no clinical symptoms and no familial history of PDB (van der Zee et al., 
2014). 
In the present FTLD-PDB family (Fig1), the co-occurrence of two pathogenic mutations was identified in two 
patients (III3 and III4). The III3, was the proband who developed both symptoms of bvFTD and PDB over the 
course of the disease whereas III4 presented only with PDB signs at 61 years of age, symptoms that are predictable 
related to the p.P392L mutation. Although this asymptomatic C9orf72 carrier still presented a preserved 
performance on executive functions, she might develop cognitive impairment later on due to the age dependent 
penetrance of the C9orf72 expansion. Indeed, in accordance with previous studies, approximately 0% of expansion 
carriers showed symptoms below 35 years, 50% of carriers younger than 58 years were still clinically asymptomatic, 
and nearly 100% of carriers were symptomatic at an age older than 80 years (Majounie et al., 2012). Actually, 
within this family, the C9orf72 carriers showed heterogeneity in clinical presentations and a wide variation in age of 
onset (ranging from 58 to 80 years). In the other examined relatives, a single C9orf72 repeat expansion or SQSTM1 
p.P392L mutations was identified and was associated with clinical signs in the spectrum of bvFTD or isolated PDB, 
respectively. To our knowledge, this is the first kindred that clearly demonstrated a co-segregation FTLD-PDB 
phenotype due to the occurrence of both mutations. Interestingly, van der zee and colleagues have also previously 
identified three FTLD patients who carried a SQSTM1 mutation and the pathogenic C9orf72 repeat expansion. 
However, they could not exclude the presence of PDB since this condition often remains asymptomatic and a 
diagnosis requires confirmatory imaging (van der Zee et al., 2014). Furthermore, our study seems to support 
previous studies demonstrating the co-occurance of 2 evidently pathogenic mutations in FTLD patients, in whom the 
C9orf72 mutation was one of the two mutations found (Ferrari et al., 2012; Lashley et al., 2014; King et al., 2013; 
Mignarri et al., 2014; van Blitterswijk et al., 2013).  
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Despite the fact that each of these mutations independently causes disease, it is tempting to speculate that when they 
co-occur they could modify the expressivity of the disease. One could hypothesize a synergistic effect of both 
genetic changes on the disease pathogenesis.  However due to the limited number of double mutation carriers in our 
family we do not have a clear indication that the co-existence of mutations influences clinical expression of disease. 
Moreover, onset age was no different from those carrying only one of the mutations. We believe that the number of 
cases with double mutations could be underestimated as the molecular strategy adopted in the vast majority of the 
laboratories ends with the identification of one pathogenic mutation in one of the known causative genes.  
In the future, moving from individual gene testing by conventional methods such as, Sanger sequencing, to deep 
sequencing methods using a known dementia genes-panel testing, will be critical to explore whether or not the 
contribution of more than one gene defect is responsible for the clinical heterogeneity seen in patients suffering from 
neurodegenerative diseases. Thus, in our family, the most recent genes linked to FTLD, C9orf72 and SQSTM1, 
appeared mutated and explain the FTLD-PDB phenotype developed. Consequently, these findings have huge 
implications in genetic counseling of both patients and family members and further elucidating studies involving the 
respective encoded proteins will be needed to rule out their engagement into the common downstream pathway in 
the disease process. 
 
 
ACKNOWLEDGEMENTS  
The Antwerp group is in part funded by the MetLife Foundation Award (to C.V.B.), the Flemish Government 
initiated Flanders Impulse Program on Networks for Dementia Research (VIND); the Belgian Science Policy 
Office Interuniversity Attraction Poles program; the Foundation for Alzheimer Research (SAO-FRA); the 
Medical Foundation Queen Elisabeth; the Flemish Government Methusalem excellence program; the Research 
Foundation Flanders (FWO) and the University of Antwerp Research Fund. 
  
CONFLICTS OF INTEREST  
 
The authors declare no conflicts of interest. 
 
 
ETHICAL STANDARDS 
 
All included family members or responsible caregivers, whichever appropriate, provided informed written consent 
for their participation in the study.  
 
REFERENCE LIST 
 
Boeve BF, Boylan KB, Graff-Radford NR, DeJesus-Hernandez M, Knopman DS, Pedraza O, Vemuri P, 
Jones D, Lowe V, Murray ME, Dickson DW, Josephs KA, Rush BK, Machulda MM, Fields JA, Ferman 
TJ, Baker M, Rutherford NJ, Adamson J, Wszolek ZK, Adeli A, Savica R, Boot B, Kuntz KM, Gavrilova 
R, Reeves A, Whitwell J, Kantarci  K, Jack CR Jr, Parisi JE, Lucas JA, Petersen RC, Rademakers R. 
8"
"
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the 
GGGGCC repeat expansion in C9ORF72. Brain 2012; Mar;135(Pt 3):765-83. doi: 10.1093/brain/aws004 
 
Bjørkøy G, Lamark T, Johansen T. p62/SQSTM1: a missing link between protein aggregates and the 
autophagy machinery. Autophagy 2006; Apr-Jun;2(2):138-9 
 
Cavey JR, Ralston SH, Sheppard PW, Ciani B, Gallagher TR, Long JE, Searle MS, Layfield R. Loss of 
ubiquitin binding is a unifying mechanism by which mutations  of SQSTM1 cause Paget's disease of bone. 
Calcif Tissue Int 2006; May;78(5):271-7 
 
Cerami C, Marcone A, Galimberti D, Zamboni M, Fenoglio C, Serpente M, Scarpini E, Cappa SF. Novel 
evidence of phenotypical variability in the hexanucleotide repeat expansion in chromosome 9. J Alzheimers 
Dis 2013; Jan 1;35(3):455-62. doi: 10.3233/JAD-122302 
 
Dejesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, 
Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, 
Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, 
Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat 
in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; Oct 
20;72(2):245-56. doi: 10.1016/j.neuron.2011.09.011 
 
Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, Zheng JG, Shi Y, Siddique N, Arrat H, Donkervoort 
S, Ajroud-Driss S, Sufit RL, Heller SL, Deng HX, Siddique T. SQSTM1 mutations in familial and sporadic 
amyotrophic lateral sclerosis. Arch Neurol 2011; Nov;68(11):1440-6. doi: 10.1001/archneurol.2011.250 
 
Ferrari R, Mok K, Moreno JH, Cosentino S, Goldman J, Pietrini P, Mayeux R, Tierney MC, Kapogiannis 
D, Jicha GA, Murrell JR, Ghetti B, Wassermann EM, Grafman J, Hardy J, Huey ED, Momeni P. Screening 
for C9ORF72 repeat expansion in FTLD. Neurobiol Aging 2012; Aug;33(8):1850.e1-11. doi: 
10.1016/j.neurobiolaging.2012.02.017 
 
Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive 
state of patients for the clinician. J Psychiatr Res 1975; Nov;12(3):189-98 
 
Galimberti D, Fenoglio C, Serpente M, Villa C, Bonsi R, Arighi A, Fumagalli GG, Del Bo R, Bruni AC, 
Anfossi M, Clodomiro A, Cupidi C, Nacmias B, Sorbi S, Piaceri I, Bagnoli S, Bessi V, Marcone A, Cerami 
C, Cappa SF, Filippi M, Agosta F, Magnani G, Comi G, Franceschi M, Rainero I, Giordana MT, Rubino E, 
Ferrero P,  Rogaeva E, Xi Z, Confaloni A, Piscopo P, Bruno G, Talarico G, Cagnin A, Clerici F, Dell'Osso 
B, Comi GP, Altamura AC, Mariani C, Scarpini E. Autosomal dominant frontotemporal lobar degeneration 
due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. Biol 
Psychiatry 2013; Sep 1;74(5):384-91. doi: 10.1016/j.biopsych.2013.01.031 
 
Gijselinck I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S, Kleinberger G, Janssens J, Bettens 
K, Van Cauwenberghe C, Pereson S, Engelborghs S, Sieben A, De Jonghe P, Vandenberghe R, Santens P, 
De Bleecker J, Maes G, Bäumer V, Dillen L, Joris G, Cuijt I, Corsmit E, Elinck E, Van Dongen J, 
Vermeulen S, Van den Broeck M, Vaerenberg C, Mattheijssens M, Peeters K, Robberecht W, Cras P, 
Martin JJ, De Deyn PP, Cruts M, Van Broeckhoven C. A C9orf72 promoter repeat expansion in a Flanders-
Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis 
spectrum: a gene identification study. Lancet Neurol 2012; Jan;11(1):54-65. doi: 10.1016/S1474-
4422(11)70261-7 
 
Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Engelborghs S, De Bleecker J, Ivanoiu A, Deryck 
O, Edbauer D, Zhang M, Heeman B, Bäumer V, Van den Broeck M, Mattheijssens M, Peeters K, Rogaeva 
E, De Jonghe P, Cras P, Martin JJ, de Deyn PP, Cruts M, Van Broeckhoven C. The C9orf72 repeat size 
correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. 
Mol Psychiatry. 2015; Oct 20. doi: 10.1038/mp.2015.159.  
9"
"
Guerreiro M, Silva AP, Botelho MA. Avaliação Breve do Estado Mental: Escalas e Testes na Demência. 
Grupo de Estudos de Envelhecimento Cerebral e Demência,2003; 27-32. 
 
Guerreiro M. Contribution of Neuropsychology to the Study of Dementias. Ph.D. thesis. 1988; Faculty of 
Medicine of Lisbon, Lisbon, Portugal. 
 
Guerreiro M, Fonseca S, Barreto J. Escalas e Testes na Demência. Grupo de Estudos de Envelhecimento 
Cerebral e Demência, 2003; 33-49. 
 
King A, Al-Sarraj S, Troakes C, Smith BN, Maekawa S, Iovino M, Spillantini MG, Shaw CE. Mixed tau, 
TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr 
MAPT (tau) variant. Acta Neuropathol 2013; Feb;125(2):303-10. doi: 10.1007/s00401-012-1050-0 
 
Kuusisto E, Salminen A, Alafuzoff  I. Ubiquitin-binding protein p62 is present  in neuronal and glial 
inclusions in human tauopathies and synucleinopathies. Neuroreport 2001; Jul 20;12(10):2085-90 
 
Kwok CT, Morris A, de Belleroche JS. Sequestosome-1 (SQSTM1) sequence variants in ALS cases in the 
UK: prevalence and coexistence of SQSTM1 mutations in ALS kindred with PDB. Eur J Hum Genet 2013; 
Aug 14. doi: 10.1038/ejhg.2013.184 
 
Lashley T, Rohrer JD, Mahoney C, Gordon E, Beck J, Mead S, Warren J, Rossor M, Revesz T. A 
pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia. 
Neuropathol Appl Neurobiol 2014; Jun;40(4):502-13. doi: 10.1111/nan.12100 
 
Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 
(SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002; Jun;70(6):1582-8  
 
Le Ber I, Camuzat A, Guerreiro R, Bouya-Ahmed K, Bras J, Nicolas G, Gabelle A, Didic M, De 
Septenville A, Millecamps S, Lenglet T, Latouche M, Kabashi E, Campion D, Hannequin D, Hardy J, 
Brice A; French Clinical and Genetic Research Network on FTD/FTD-ALS. SQSTM1 mutations in French 
patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. 
JAMA Neurol 2013; Nov;70(11):1403-10. doi: 10.1001/jamaneurol.2013.3849 
 
Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chiò A, Restagno G, Nicolaou N, 
Simon-Sanchez J, van Swieten JC, Abramzon Y, Johnson JO,  Sendtner M, Pamphlett R, Orrell RW, Mead 
S, Sidle KC, Houlden H, Rohrer JD, Morrison KE, Pall H, Talbot K, Ansorge O; Chromosome 9-ALS/FTD 
Consortium; French research network on FTLD/FTLD/ALS; ITALSGEN Consortium, Hernandez DG, 
Arepalli S, Sabatelli M, Mora G, Corbo M, Giannini F, Calvo A, Englund E, Borghero G, Floris  GL, 
Remes AM, Laaksovirta H, McCluskey L, Trojanowski JQ, Van Deerlin VM, Schellenberg GD, Nalls MA, 
Drory VE, Lu CS, Yeh TH, Ishiura H, Takahashi Y, Tsuji S, Le Ber I, Brice A, Drepper C, Williams N, 
Kirby J, Shaw P, Hardy J, Tienari PJ, Heutink P, Morris HR, Pickering-Brown S, Traynor BJ. Frequency of 
the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and 
frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; Apr;11(4):323-30. doi: 
10.1016/S1474-4422(12)70043-1 
 
 McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ; Work Group on 
Frontotemporal Dementia and Pick's Disease. Clinical and pathological diagnosis of frontotemporal 
dementia: report of the Work Group on Frontotemporal  Dementia and Pick's Disease. Arch Neurol 2001; 
Nov;58(11):1803-9 
 
Michou L, Collet C, Morissette J, Audran M, Thomas T, Gagnon E, Launay JM, Laplanche JL, Brown JP, 
Orcel P. Epidemiogenetic study of French families with Paget's disease of bone. Joint Bone Spine 2012;  
Jul;79(4):393-8. doi: 10.1016/j.jbspin.2011.07.005 
 
10"
"
Mignarri A, Battistini S, Tomai Pitinca ML, Monti L, Burroni L, Ginanneschi F, Ricci C, Bavazzano A, 
Federico A, Restagno G, Dotti MT. Double trouble? Progranulin mutation and C9ORF72 repeat expansion 
in a case of primary non-fluent aphasia. J Neurol Sci 2014; Jun 15;341(1-2):176-8. doi: 
10.1016/j.jns.2014.03.030 
 
Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing 
treatment efficacy. Psychopharmacol Bull 1983; 19(3):448-50 
 
Murray ME, DeJesus-Hernandez M, Rutherford NJ, Baker M, Duara R, Graff-Radford NR, Wszolek ZK, 
Ferman TJ, Josephs KA, Boylan KB, Rademakers R, Dickson DW. Clinical and neuropathologic 
heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta 
Neuropathol 2011; Dec;122(6):673-90. doi: 10.1007/s00401-011-0907-y 
 
Najat D, Garner T, Hagen T, Shaw B, Sheppard PW, Falchetti A, Marini F, Brandi ML, Long JE, Cavey 
JR, Searle MS, Layfield R. Characterization of a non-UBA domain missense mutation of sequestosome 1 
(SQSTM1) in Paget's disease of bone. J Bone Miner Res 2009; Apr;24(4):632-42. doi: 
10.1359/jbmr.081204 
 
Nakaso K, Yoshimoto Y, Nakano T, Takeshima T, Fukuhara Y, Yasui K, Araga S, Yanagawa T, Ishii T, 
Nakashima K. Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: possible 
mechanisms and the role in Lewy  body formation in Parkinson's disease. Brain Res 2004; Jun 25;1012(1-
2):42-51 
 
Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, 
Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus 
on clinical diagnostic criteria. Neurology 1998; Dec;51(6):1546-54 
 
Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Øvervatn A, Bjørkøy G, Johansen T. 
p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by 
autophagy. J Biol Chem 2007; Aug 17;282(33):24131-45 
 
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, 
Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson 
JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, 
Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson 
BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y,  Chow TW, Manes F, Grafman J, 
Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the 
behavioural variant of frontotemporal dementia. Brain 2011; Sep;134(Pt 9):2456-77. doi: 
10.1093/brain/awr179 
 
Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, 
van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz 
SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, 
Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, 
Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, 
Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Holtta-Vuori M, Ikonen E, Sulkava R, 
Benatar M, Wuu J, Chio A, Restagno G, Borghero G, Sabatelli M, Heckerman D, Rogaeva E, Zinman L, 
Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy 
J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ. A 
hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 
2011; Oct 20;72(2):257-68. doi: 10.1016/j.neuron.2011.09.010 
 
Rubino E, Rainero I, Chiò A, Rogaeva E, Galimberti D, Fenoglio P, Grinberg Y, Isaia G, Calvo A, Gentile 
S, Bruni AC, St George-Hyslop PH, Scarpini E, Gallone S, Pinessi L. TODEM Study Group. SQSTM1 
11"
"
mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 2012; Oct 
9;79(15):1556-62. doi: 10.1212/WNL.0b013e31826e25df 
 
Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. Sequestosome 1/p62 is a 
polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 2004; 
Sep;24(18):8055-68 
 
Snowden JS, Rollinson S, Thompson JC, Harris JM, Stopford CL, Richardson AM, Jones M, Gerhard A, 
Davidson YS, Robinson A, Gibbons L, Hu Q, DuPlessis D, Neary  D, Mann DM, Pickering-Brown SM. 
Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 
mutations. Brain 2012; Mar;135(Pt 3):693-708. doi: 10.1093/brain/awr355 
 
Teyssou E, Takeda T, Lebon V, Boillée S, Doukouré B, Bataillon G, Sazdovitch V, Cazeneuve C, 
Meininger V, LeGuern E, Salachas F, Seilhean D, Millecamps S. Mutations in SQSTM1 encoding p62 in 
amyotrophic lateral sclerosis: genetics and neuropathology. Acta Neuropathol 2013; Apr;125(4):511-22. 
doi: 10.1007/s00401-013-1090-0 
 
The Lund  and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J 
Neurol Neurosurg Psychiatry 1994; Apr;57(4):416-8 
 
Vadlamudi RK, Joung I, Strominger JL, Shin J. p62, a phosphotyrosine-independent ligand of the SH2 
domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 1996; Aug 
23;271(34):20235-7 
 
van Blitterswijk M, Baker MC, DeJesus-Hernandez M, Ghidoni R, Benussi L, Finger E, Hsiung GY, 
Kelley BJ, Murray ME, Rutherford NJ, Brown PE, Ravenscroft T, Mullen B, Ash PE, Bieniek KF, 
Hatanpaa KJ, Karydas A, Wood EM, Coppola G, Bigio EH, Lippa C, Strong MJ, Beach TG, Knopman DS, 
Huey ED, Mesulam M, Bird T, White CL 3rd, Kertesz A, Geschwind DH, Van Deerlin VM, Petersen RC, 
Binetti G, Miller BL, Petrucelli L, Wszolek ZK, Boylan KB, Graff-Radford NR, Mackenzie IR, Boeve BF, 
Dickson DW, Rademakers R. C9ORF72 repeat expansions in cases with previously identified pathogenic 
mutations. Neurology 2013; Oct 8;81(15):1332-41. doi: 10.1212/WNL.0b013e3182a8250c 
 
van der Zee J, Gijselinck I, Dillen L, Van Langenhove T, Theuns J, Engelborghs S, Philtjens S, 
Vandenbulcke M, Sleegers K, Sieben A, Bäumer V, Maes G, Corsmit E, Borroni B, Padovani A, Archetti 
S, Perneczky R, Diehl-Schmid J, de Mendonça A, Miltenberger-Miltenyi G, Pereira S, Pimentel J, Nacmias 
B, Bagnoli S, Sorbi S, Graff C, Chiang HH, Westerlund M, Sanchez-Valle R, Llado A, Gelpi E, Santana I, 
Almeida MR, Santiago B, Frisoni G, Zanetti O, Bonvicini C, Synofzik M, Maetzler W, Vom Hagen JM, 
Schöls L, Heneka MT, Jessen F, Matej R, Parobkova E, Kovacs GG,  Ströbel T, Sarafov S, Tournev I, 
Jordanova A, Danek A, Arzberger T, Fabrizi GM, Testi S, Salmon E, Santens P, Martin JJ, Cras P, 
Vandenberghe R, De Deyn PP, Cruts M, Van Broeckhoven C, van der Zee J, Gijselinck I, Dillen L, Van 
Langenhove T, Theuns J, Philtjens S, Sleegers K, Bäumer V, Maes G, Corsmit E, Cruts M, Van 
Broeckhoven C, van der Zee J, Gijselinck I, Dillen L, Van Langenhove T, Philtjens S, Theuns J, Sleegers 
K, Bäumer V, Maes G, Cruts M, Van Broeckhoven C, Engelborghs S, De Deyn PP, Cras P, Engelborghs S, 
De Deyn PP, Vandenbulcke M, Vandenbulcke M, Borroni B, Padovani A, Archetti S, Perneczky R, Diehl-
Schmid J, Synofzik M, Maetzler W, Müller Vom Hagen J, Schöls L, Synofzik M, Maetzler W, Müller Vom 
Hagen J, Schöls L, Heneka MT, Jessen F, Ramirez A, Kurzwelly D, Sachtleben C, Mairer W, de Mendonça 
A, Miltenberger-Miltenyi G, Pereira S, Firmo  C, Pimentel J, Sanchez-Valle R, Llado A, Antonell A, 
Molinuevo J, Gelpi E, Graff  C, Chiang HH, Westerlund M, Graff C, Kinhult Ståhlbom A, Thonberg H, 
Nennesmo I,  Börjesson-Hanson A, Nacmias B, Bagnoli S, Sorbi S, Bessi V, Piaceri I, Santana I, Santiago 
B, Santana I, Helena Ribeiro M, Rosário Almeida M, Oliveira C, Massano J, Garret C, Pires P, Frisoni G, 
Zanetti O, Bonvicini C, Sarafov S, Tournev I, Jordanova A, Tournev I, Kovacs GG, Ströbel T, Heneka MT, 
Jessen F, Ramirez A, Kurzwelly D, Sachtleben C, Mairer W, Jessen F, Matej R, Parobkova E, Danel A, 
Arzberger T, Maria Fabrizi G, Testi S, Ferrari S, Cavallaro T, Salmon E, Santens  P, Cras P. European 
Early-Onset Dementia Consortium. A pan-European study of the C9orf72 repeat associated with FTLD: 
12"
"
geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat 2013; Feb;34(2):363-73. 
doi: 10.1002/humu.22244 
 
van der Zee J, Van Langenhove T, Kovacs GG, Dillen L, Deschamps W, Engelborghs S, Matěj R, 
Vandenbulcke M, Sieben A, Dermaut B, Smets K, Van Damme P, Merlin C,  Laureys A, Van Den Broeck 
M, Mattheijssens M, Peeters K, Benussi L, Binetti G, Ghidoni R, Borroni B, Padovani A, Archetti S, Pastor 
P, Razquin C, Ortega-Cubero  S, Hernández I, Boada M, Ruiz A, de Mendonça A, Miltenberger-Miltényi 
G, do Couto FS, Sorbi S, Nacmias B, Bagnoli S, Graff C, Chiang HH, Thonberg H, Perneczky R, Diehl-
Schmid J, Alexopoulos P, Frisoni GB, Bonvicini C, Synofzik M, Maetzler W, vom Hagen JM, Schöls L, 
Haack TB, Strom TM, Prokisch H, Dols-Icardo O, Clarimón J, Lleó A, Santana I, Almeida MR, Santiago 
B, Heneka MT, Jessen F, Ramirez A, Sanchez-Valle R, Llado A, Gelpi E, Sarafov S, Tournev I, Jordanova 
A, Parobkova E, Fabrizi GM, Testi S, Salmon E, Ströbel T, Santens P, Robberecht W, De Jonghe P, Martin 
JJ, Cras P, Vandenberghe R, De Deyn PP, Cruts M, Sleegers K, Van Broeckhoven C. Rare mutations in 
SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathol 2014; 
Sep;128(3):397-410. doi:10.1007/s00401-014-1298-7 
 
Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M, Aguzzi 
A, Denk H. p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J 
Pathol 2002; Jan;160(1):255-63  
 
13"
"
FIGURES 
 
Fig 1- Pedigree of the Family with FTD-PDB phenotype carrying c.1175C>T, p.P392L, mutation and concomitant 
long C9orf72 hexanucleotide expansion (>80 units).  
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The black symbols represent patients affected with frontal cognitive impairment or dementia (left side filled), Paget 
disease of bone (right side filled) or both. The grey symbol indicates signs of cognitive impairment resulting from 
childhood encephalitis (left side filled). The black horizontal stripes (right side filled) indicate Parkinsonism. White 
symbols represent unaffected individuals. Age of onset in years (y) are shown below symbols (top number) and age 
of death (bottom number) is also shown for the proband who died. The proband is indicated by an arrow. Individuals 
with obtainable DNA are shown with an asterisk to the right of the symbol. The Roman numeral to the left of the 
pedigree denotes the generation; Arabic numbers below the individuals denote individuals. The results of the genetic 
analysis of C9orf72 expansion and SQSTM1 genes appeared inside brackets. mni: no mutation identified; expansion 
G4C2: carrier of the hexanucleotide repeat expansion in C9orf72; p.P392L: carrier of the heterozygous p.P392L 
mutation in exon 8 of the SQSTM1. 
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Fig 2 - Bone scintigraphy with 99mTc-MDP showing multifocal anomalous hypercaptation, specially in axial 
skeleton, consistent with Paget’s disease. The patient had also Lumbosacral spine CT revealing structural bone 
deformation.  
 
 
 
 
 
 
Fig 3 - (a) Axial and sagittal gadolinium enhanced T1-weighted and (b) axial T2-weighted fluid-attenuated inversion 
recovery (FLAIR) brain MRI showing cortical-subcortical left parietal atrophy.  
a b 
 
Images are displayed according to radiological convention (right side of the brain is shown on the left side of 
figure). 
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Fig 4 - Cerebral SPECT (HMPAO single-photon emission computed tomography) revealed hypoperfusion mainly in 
the frontal lobe including the upper frontal and pre and post central gyrus, predominantly on the left-side. 
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Table#1#–#Summary#of#the#genetic,#phenotypic#and#imaging#information#from#all#evaluated#family#members##
 Mutation#status! # Clinical#phenotype# Imaging#data#
Case#
C9orf72#
repeat#
expansion#
SQSTM1,#
p.P392L#
Investigation#
(Age/years)#
Cognitive#
impairment#
Other#
neurological#
signs#
Paget# Brain#imaging# Bone#scintigraphy#
II1# n/a# n/a# L# Dementia#######(60#years)# Parkinsonism# Possible# n/a# n/a#
II2# n/a# n/a# L# No#####################(90#years)# Parkinsonism# No# n/a# n/a#
II4# +# L# 80# Dementia##########(81#years)# No# No#
MRI#=#Asymetric#atrophy#
(hipocampus)#
#
PiBLPET#=#negative#
negative#
III1# +# L# 69#
Frontal#
Cognitive#
Impairment#
No# No# Not#done# negative#
III2# +# L# 65#
Frontal#
Cognitive#
Impairment#
No# No# Not#done# negative#
III3# +# +# 58# Dementia#########(58#years)#
Tetraparesis,#
grasp#reflexes# yes#
MRI#=#CorticalLsubcortical#left#
hemisphere#atrophy#
#
SPECT#=#frontal#hypoperfusion#
positive#
III4# +# +# 60# No############### No# yes# Not#done# positive#
III5# L# +# 57#
Mental#
Developmental#
Disorder#
No# yes# Not#done# positive#
III6# L# L# 52# No# No# No# Not#done# negative#
#
n/a=not available; + = present; - = absent; SPECT= Single Photon Emission Computed Tomography; MRI= Magnetic)resonance)imaging; Pittsburgh 
Compound-B (PiB) positron emission tomography (PET);  
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Table2 – Individual neuropsychological and psychological data available for the evaluated cases 
 #II4 #III1 #III2 &III3 &III4 ¤III5 III6 
Behavior*)        
#####Impulsivity# /# √# √# √# /# /# /#
#####Rigidity/perseveration# /# /# √# √# /# /# /#
#####Apathy# √# /# /# √# /# √# /#
#####Loss#of#attention# √# √# √# √# # √# /#
MMSE#(≤22)**# 22/30# 29/30# 30/30# 23/30# 30/30# 24/30# 28/30#
MoCA)(<17)**) 18/30# 23/30# 24/30# n/a# 30/30# 13/30# 28/30#
Comprehensive)Neuropsychological)Assessment*)
Executive# # # # # # # #
#####Psychomotor#slowing# √# /# /# √# /# √# /#
#####Sequencing#impairment# √# √# /# √# /# /# /#
#####Verbal/#motor#perseveration## /# /# /# √# /# /# /#
#####Generation#impairment# √# /# /# √# /# /# /#
#####Planning#/set#shifting#impairment# √# √# √# √# /# √# /#
#####Impairment#abstraction# /# /# /# √# /# √# /#
Language# # # # # # # #
#####Reduced#fluency# /# /# /# √# /# /# /#
#####Word#finding#difficulty# /# /# /# /# /# /# /#
#####Comprehension#deficit# /# /# /# /# /# /# /#
#####Echolalia# /# /# /# √# /# /# /#
Memory# # # # # # # #
#####Short#term#impairment# /# /# /# /# /# √# /#
#####Retrograde#information# /# /# /# /# /# √# /#
#####Verbal#learning#impairment# √# /# /# √# /# √# /#
#####Verbal#consolidation#impairment# √# /# /# /# /# /# /#
#####Visual#learning#impairment# √# /# √# √# /# /# /#
#####Visual#consolidation#impairment# √# √# √# /# /# /# /#
Visuospatial#construction#impairment# /# /# /# /# /# /# /#
Apraxia# /# # # /# /# /# /#
#
MoCA%= The Montreal Cognitive Assessment; MMSE=%The%Mini.Mental%State%Examination;% √= present; - = absent;  
# = C9orf72 expansion carrier; &=double mutation carrier; ¤= SQSTM1 p. P392L carrier  
* Qualitative evaluation of specific domains   
**Cut off for Dementia considering the normative data for the Portuguese population 
 
 
 
 
